Insight

Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer

Photo of Joe Lennerz from pathologyoutlines.com

Apr 12, 2024, 05:34

Joe Lennerz: Quickly sharing a fantastic paper on tumour infiltrating lymphocytes in triple-negative breast cancer

Joe Lennerz, Chief Scientific Officer at BostonGene, shared on LinkedIn:

“Quickly sharing a fantastic paper on tumour infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC). Bottom line: In patients with early-stage TNBC who did not undergo adjuvant or neoadjuvant chemotherapy, breast cancer tissue with a higher abundance of TIL levels was associated with significantly better survival.

These results suggest that breast tissue TIL abundance is a prognostic factor for patients with early-stage TNBC. Link to publication.”

Source: Joe Lennerz/LinkedIn

adjuvant chemotherapy BostonGene Breast Cancer cancer Joe Lennerz neoadjuvant chemotherapy OncoDaily Oncology TNBC triple-negative breast cancer tumour infiltrating lymphocytes (TIL)

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage